ABSTRACT
Objective To investigate the clinical value of combined detection of serum miRNA-210 and miRNA-21 in non small cell lung cancer (NSCLC).Methods Forty-eight patients with NSCLC in the Bazhong Municipal Central Hospital were selected as the research subjects.Forty patients with benign lung diseases and 40 individuals undergoing healthy physical examination were selected as the control groups.The levels of serum miRNA-210 and miRNA-21were detected by RT-qPCR.Results The levels of serum miRNA-210 and miRNA-21 in the patients with NSCLC were significantly higher than those in the patients with benign lung diseases and healthy controls(P＜0.05);serum miRNA-210 was highly expressed in adenocarcinoma and T3-4 stage patients(P＜0.05) and miRNA-210 was highly expressed in adenocarcinoma,T3-4 stage and smoking patients(P＜0.05);the area under the ROC curve(AUC) of miRNA-210 and miRNA-21 for diagnosing NSCLC was 0.845 and 0.725 respectively,but AUC of their combination was 0.928 (P =0.021);COX multivariate regression analysis showed that serum miRNA-210 (RR:1.977,95 ％ CI:0.985-3.018,P =0.009) and miRNA-21 (RR:1.853,95％ CI:0.921-2.776,P =0.018) had some predictive value for the prognosis in the patients with NSCLC.Conclusion MiRNA-210 and miRNA-21 are highly expressed in serum of the patients with NSCLC.Their combined detection can have a certain diagnostic efficiency for NSCLC and have a certain prompt action on the prognosis.
ABSTRACT
In order to improve diagnostic method to Babesia gibsoni infection,gene recombination technique was used in our study.By this technique,we constructed and expressed recombinant apical membrane antigen-1(BgAMA-1),and recombinant BgAMA-1 was used in ELISA experiment as diagnostic antigen.The results showed the recombinant expressed plasmid was triumphantly constructed and the recombinant antigen BgAMA-1 had a high specificity in ELISA test.These results demonstrate that the recombinant BgAMA-1 might be a useful diagnostic reagent for detection of antibodies to B.gibsoni in dogs.